Am J Pathol
- TAN PK, Ostertag T, Rosenthal SB, Chilin-Fuentes D, et al
Role of Hepatic Stellate and Liver Sinusoidal Endothelial Cells in a Human
Primary Cell Three-Dimensional Model of Nonalcoholic Steatohepatitis.
Am J Pathol. 2023 Dec 28:S0002-9440(23)00484.
Gastroenterology
- XIE L, Guo H
Question on the use of BMI >/= 25 kg/m(2) to define obesity to analyze the
incidence and risk factors of hepatic steatosis and hepatic fibrosis in the
Chinese population.
Gastroenterology. 2023 Sep 8:S0016-5085(23)04983.
Gut
- EL-SERAG H, Kanwal F, Ning J, Powell H, et al
Serum biomarker signature is predictive of the risk of hepatocellular cancer in
patients with cirrhosis.
Gut. 2024 Feb 16:gutjnl-2024-332034. doi: 10.1136/gutjnl-2024-332034.
Hepatology
- SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al
Lack of complete biochemical response in autoimmune hepatitis leads to adverse
outcome: first report of the IAIHG retrospective registry.
Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589.
- LEE BP, Dodge JL, Terrault NA
National prevalence estimates for steatotic liver disease and subclassifications
using consensus nomenclature.
Hepatology. 2024;79:666-673.
- WANG F, Chen L, Kong D, Zhang X, et al
Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an
LDH-A/HIF-1alpha transcriptional complex.
Hepatology. 2024;79:606-623.
- NICOARA-FARCAU O, Han G, Rudler M, Angrisani D, et al
Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised
individual patient data meta-analysis.
Hepatology. 2024;79:624-635.
- MA S, Chew V
Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated
hepatocellular carcinoma.
Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000626.
- PREMKUMAR M, Kajal K, Izzy M, Sihag BK, et al
Reply to 'liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus".
Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000792.
- CALTHORPE L, Chiou SH, Rubin J, Huang CY, et al
A modified hospital frailty risk score for patients with cirrhosis undergoing
abdominal operations.
Hepatology. 2024 Feb 19. doi: 10.1097/HEP.0000000000000794.
- PENG Z, Wei G, Huang P, Matta H, et al
ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals"
from hepatocytes and suppresses progression to cirrhosis and liver cancer.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000801.
- ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure
features a natural killer cell signature.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
- WONG YJ, Teng M, Sim A, Thet HM, et al
Full adherence to cirrhosis quality indicators is associated with lower mortality
in acute variceal bleeding: Nationwide audit.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000793.
J Hepatol
- GE X, Desert R, Magdaleno F, Han H, et al
Redox-sensitive high-mobility group box-1 isoforms contribute to liver fibrosis
progression and resolution in mice.
J Hepatol. 2024;80:482-494.
- BENDIXEN SM, Jakobsgaard PR, Hansen D, Hejn KH, et al
Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte
signaling module.
J Hepatol. 2024;80:467-481.
- LARRUE H, Bureau C, D'Amico G
Reply to: "Comment on 'TIPS prevents further decompensation and improves survival
in patients with cirrhosis and portal hypertension in an individual patient data
meta-analysis'": Further decompensation should now be used as a clinically
relevant outc
J Hepatol. 2024;80:e109-e110.
N Engl J Med
- KOWDLEY KV, Bowlus CL, Levy C, Akarca US, et al
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
N Engl J Med. 2023 Nov 13. doi: 10.1056/NEJMoa2306185.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016